Oncology reimbursement alerts

Alecensa, an oral medication, will fall under Medicare Part D for drug coverage. As it is a new molecular entity and an orphan drug, billing teams should monitor for specific coding and formulary upda

WELIREG (Belzutifan) is an oral medication and will fall under Medicare Part D for coverage. There are no applicable J-codes as it is not an injectable drug, and existing alternatives may affect adopt

KEYTRUDA QLEX, an injectable drug approved under BLA761467, will be billed under Part B. Billing teams should verify the specific J-code upon FDA label publication.

With the approval of TZIELD (teplizumab-mzwv) as an injectable, it is expected to receive a J-code assignment for Medicare billing under Part B. A payment model of ASP + 6% may be applicable, and give

Keytruda (pembrolizumab) is an injectable drug that is administered intravenously, likely to receive a J-code for billing under Medicare Part B. Given its classification as an orphan drug and its rele

Yervoy (ipilimumab) is an injectable drug that may be assigned a J-code for Medicare billing, as it qualifies for Part B coverage due to its injectable nature. It is an orphan drug, which could indica

OPDUALAG, an intravenous injectable drug, will likely receive a specific J-code for Medicare billing due to its status as a new molecular entity. Since it is an oncology drug, it may be eligible for p

As Voranigo (vorasidenib) is an oral tablet, it will be billed under the Part D pathway. Billing teams should confirm details against the FDA label for any updates related to the drug's billing specif

As a newly approved subcutaneous injectable, Hympavzi can be billed under Part B. Billing teams should confirm the details regarding its pricing and specific J-code once the FDA label is published.

The proposed LCD by Noridian regarding non-next generation sequencing tests may significantly impact billing for BCR-ABL negative myeloproliferative neoplasms by establishing new criteria for coverage

The proposed LCD regarding the off-label use of Rituximab and its biosimilars may significantly impact billing practices, as it could lead to changes in coverage policies for these medications. Such m

The proposed LCD on biomarker testing for risk stratification in DCIS could significantly influence billing practices by establishing clear criteria for reimbursement. Providers will need to ensure th

The proposed LCD for MolDX biomarker testing in DCIS could impact billing by establishing clear criteria for reimbursement, potentially increasing the number of eligible tests approved for coverage. T

The proposed Local Coverage Determination (LCD) for MolDX regarding biomarker testing in Ductal Carcinoma In Situ (DCIS) could significantly influence billing by establishing clear guidelines for reim

The proposed LCD could significantly impact billing for biomarker testing in patients with Ductal Carcinoma In Situ (DCIS). Practices may need to adjust their coding and documentation to align with ne

The proposed Local Coverage Determination (LCD) for Non-Next Generation Sequencing Targeted Molecular Panel Tests could significantly impact billing for oncology practices by defining reimbursement cr

The proposed LCD on non-next generation sequencing targeted molecular panel tests may significantly impact billing practices for oncology providers. By establishing guidelines for which tests are elig

The proposed LCD could potentially impact billing for non-next generation sequencing targeted molecular panel tests used in cancer predictive testing. This may lead to increased scrutiny and changes i

The proposed Local Coverage Determination (LCD) could significantly affect billing practices for non-next generation sequencing targeted molecular panel tests used in cancer predictive testing. It is

The proposed Local Coverage Determination (LCD) for Irreversible Electroporation (IRE) could significantly impact reimbursement for cancer treatments. If approved, this will allow healthcare providers

The introduction of the Breast Cancer Index® test by Palmetto GBA is affecting the precision of breast cancer treatment decisions. As this test becomes effective in July 2025, providers will need

The introduction of predictive classifiers for early-stage non-small cell lung cancer will have significant implications for billing practices. Providers may need to adjust their coding and documentat

The implementation of the MolDX Prostate Cancer Genomic Classifier Assay is expected to supports compliance with updated rates processes by providing clear coverage guidelines for prostate cancer diagnostics. This could lea

The introduction of LCD MolDX for Phenotypic Biomarker Detection in Circulating Tumor Cells may lead to increased compliance updates for oncology providers. Proper coding and documentation will be

The introduction of MolDX for risk-stratifying patients at increased risk for prostate cancer may lead to supports compliance with updated rates opportunities for laboratories performing these biomarker tests. This c

The off-label use of Rituximab and its biosimilars may lead to billing challenges under Medicare, as reimbursement is typically based on FDA-approved indications. Providers should ensure comprehensive

The upcoming implementation of the NRAS Genetic Testing LCD by WPS will significantly influence billing procedures for oncology-related services. Providers should anticipate changes in claims submissi

The implementation of the MolDX LCD for phenotypic biomarker detection from circulating tumor cells will create significant changes in how tests are reimbursed under Medicare. Providers will need to p

The off-label use of Rituximab and its biosimilars may lead to supports compliance with updated rates process, as insurers may require more documentation to justify its medical necessity. Providers sho

The implementation of the MGMT Promoter Methylation Analysis LCD may significantly affect billing practices for molecular diagnostics in oncology. Providers will need to ensure compliance with the new

The introduction of next-generation sequencing for solid tumors under the MolDX program may enhance the precision of diagnostics and treatment plans, positively impacting patient outcomes. However, pr

The MolDX: NRAS Genetic Testing LCD by CGS, effective from 08/21/2025, may significantly impact billing practices for genetic testing in oncology. Providers will need to familiarize themselves with th

The implementation of the MGMT Promoter Methylation Analysis LCD requires billing team review. Additionally, this L

The implementation of the LCD for Oncotype DX® Breast Cancer testing for DCIS could significantly impact billing by providing clear guidelines on coverage and reimbursement for genomic tests. This wil

The implementation of Proton Beam Therapy LCD by CGS could significantly impact billing for facilities utilizing this advanced treatment. It allows for more precise reimbursement guidelines which may

The introduction of LCD for In Vitro Chemosensitivity & Chemoresistance Assays will significantly influence billing practices in oncology, as providers will need to familiarize themselves with new doc

The introduction of the LCD for In Vitro Chemosensitivity and Chemoresistance Assays by Noridian may affect billing practices for oncology services, specifically regarding the appropriate use of relat

The new coverage for the Breast Cancer Index® test may significantly affect billing for oncology practices, allowing for additional reimbursements in relevant patient populations. Accurate coding is e

The introduction of the LCD for Minimal Residual Disease Testing will create a structured approach to billing for cancer diagnostics, potentially increasing revenue for oncology departments. As this t

The upcoming LCD for Oncotype DX® Breast Cancer testing for DCIS may significantly affect billing procedures for Oncology practices. Providers will need to ensure that appropriate documentation is ava

The introduction of the LCD for Bladder/Urothelial Tumor Markers signifies a future billing change impacting how these lab tests are reimbursed. Providers must prepare for the effective date by ensuri

The implementation of the MolDX LCD for Minimal Residual Disease Testing will significantly impact billing practices for oncology services. Providers will need to familiarize themselves with the new g

The new LCD for predictive classifiers in early stage non-small cell lung cancer will have a significant impact on billing practices, as it establishes criteria for their coverage under Medicare. Prov

The updated LCD on Bladder/Urothelial Tumor Markers by Noridian may impact billing processes for labs performing these tests. It's crucial for providers to ensure that the services provided align with

The addition of Inivata™ and InVisionFirst® liquid biopsy tests for lung cancer will enhance the diagnostic capabilities for Medicare patients while introducing potential billing complexity. Effective

The new LCD on Radiation Therapies by Palmetto GBA may affect billing practices significantly. Providers must ensure compliance with the updated guidelines to avoid claim denials and ensure proper rei

The implementation of the Bisphosphonate Drug Therapy LCD by WPS effective January 1, 2026, will necessitate adjustments in billing procedures related to bone density therapies. Providers will need to

The new local coverage determination (LCD) for immunosuppressive drugs will likely influence billing practices significantly. Providers must ensure that they comply with the updated guidelines to avoi

The implementation of the LCD for Oral Anticancer Drugs will likely standardize the billing processes, ensuring providers are adequately reimbursed for these medications. The focus on evidence-based c

The transition from intravenous to oral antiemetic drugs may lead to an supports compliance with updated rates due to the higher administration of oral medications. This change could improve patient complianc